Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2024

Primary Completion Date

November 19, 2024

Study Completion Date

November 19, 2024

Conditions

Solid Tumor

Interventions

DRUG

Technetium [99mTc]-H7ND injection

Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor

Trial Locations (1)

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors

lead

Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.

OTHER

NCT06443710 - Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers | Biotech Hunter | Biotech Hunter